Olaparib (300 mg BID)
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, p53abn
Trial Timeline
Jun 26, 2024 → Dec 1, 2031
NCT ID
NCT06712472About Olaparib (300 mg BID)
Olaparib (300 mg BID) is a phase 3 stage product being developed by AstraZeneca for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06712472. Target conditions include Endometrial Cancer, p53abn.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06712472 | Phase 3 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer